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Abstract
Objective—To provide background information for strengthening cervical cancer prevention in 
the Pacific by mapping current human papillomavirus (HPV) vaccination and cervical cancer 
screening practices, as well as intent and barriers to the introduction and maintenance of national 
HPV vaccination programmes in the region.
Materials and Methods—A cross-sectional questionnaire-based survey among ministry of 
health officials from 21 Pacific Island countries and territories (n=21).
Results—Cervical cancer prevention was rated as highly important, but implementation of 
prevention programs were insufficient, with only two of 21 countries and territories having 
achieved coverage of cervical cancer screening above 40%. Ten of 21 countries and territories had 
included HPV vaccination in their immunization schedule, but only two countries reported 
coverage of HPV vaccination above 60% among the targeted population. Key barriers to the 
introduction and continuation of HPV vaccination were reported to be: (i) Lack of sustainable 
financing for HPV vaccine programs; (ii) Lack of visible government endorsement; (iii) Critical 
public perception of the value and safety of the HPV vaccine; and (iv) Lack of clear guidelines 
and policies for HPV vaccination.
Conclusion—Current practices to prevent cervical cancer in the Pacific Region do not match the 
high burden of disease from cervical cancer. A regional approach, including reducing vaccine 
prices by bulk purchase of vaccine, technical support for implementation of prevention programs, 
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operational research and advocacy could strengthen political momentum for cervical cancer 
prevention and avoid risking the lives of many women in the Pacific.
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Introduction
Infection with oncogenic types of the sexually transmitted human papillomavirus (HPV) is a 
prerequisite for the development of cervical cancer (Walboomers et al., 1999). Of the 
528,000 new cervical cancer cases globally each year, 85% occur in low-income countries, 
where it ranges between the first to fourth most common type of cancer in women (Ferlay et 
al., 2015). Despite the existence of evidence based primary and secondary prevention 
measures, 266,000 women die throughout the world each year from cervical cancer. The 
vast majority of these deaths occur in low-income countries (Ferlay et al., 2010; Ferlay et 
al., 2015). Primary prevention by high coverage of vaccination against the highly prevalent 
oncogenic HPV genotypes 16 and 18 among girls before sexual debut has the potential to 
reduce the global burden of cervical cancer by 70–80% (WHO, 2009). Secondary prevention 
by screening and treatment of pre-cancerous lesions in young and middle aged women has 
been shown to reduce the incidence of and mortality from cervical cancer substantially in 
countries with well established health systems and has also recently been demonstrated to be 
effective in low-income countries (Denny and Anorlu, 2012).
Low- and middle income countries currently face considerable barriers for the prevention of 
cervical cancer. The most commonly mentioned barriers for introduction of HPV 
vaccination include: i) the high price of the HPV vaccine; ii) lack of effective 
communication and partnerships for building political momentum and support among health 
authorities, professional organizations, opinion leaders as well as direct beneficiaries; iii) 
lack of functioning delivery systems for achieving high vaccination coverage among 
adolescents; and (iv) lack of monitoring systems to measure coverage and effectiveness of 
the vaccination program (Garland et al., 2008b; Garland, 2009; Denny and Anorlu, 2012; 
Tsu et al., 2013).
Since 1947, 22 Pacific Island countries and territories (hereafter referred to as the Pacific 
Region) from Polynesia, Micronesia and Melanesia, with a population of approximately 
10.5 million (Secretariat of the Pacific Community, 2013), have collaborated for 
development, including public health strengthening, through the regional inter-governmental 
organization Secretariat of the Pacific Community (SPC) (Secretariat of the Pacific 
Community, 2011). A systematic review of cervical cancer incidence and mortality found 
that the annual age standardized incidence and mortality rates for cervical cancer in the 
Pacific Region ranges between 8.2–50.7/100,000 and 2.7–23.9/100,000 respectively. This 
translates into approximately 800 new cases of cervical cancer and 500 preventable deaths 
per year (Parkin et al., 2008; Foliaki et al., 2011; IARC, 2012; Obel et al., 2014). The 
Melanesian island countries rank among the highest cervical cancer incidence and mortality 
rates in the world (Ferlay et al., 2010; Garland et al., 2012; IARC, 2012) and recent cancer 
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registration from the Micronesian islands found similarly high cervical cancer incidence 
with the great majority of cases diagnosed at advanced stages (stage II or higher) which is 
beyond the on-island treatment capacity (Buenconsejo-Lum et al., 2014). Despite the high 
burden of disease, only a few studies of HPV and cervical cancer have been conducted in the 
Pacific Region, and there is no updated regional information published regarding screening 
and vaccination practices in the Pacific Region.
As a means of identifying gaps and to help facilitate initiatives for strengthening cervical 
cancer prevention in the Pacific Region, the present study maps the current HPV vaccination 
and cervical cancer screening practices in the Pacific Region as well as the views of 
Ministry of Health officials in the region on the importance of the prevention programs and 
barriers to implementation of HPV vaccination in their countries.
Materials and Methods
The study used a cross-sectional, questionnaire-based survey design to assess current 
vaccination and screening practices in the Pacific Region, the perceived importance of 
cervical cancer screening and HPV vaccination as well as barriers to introducing and 
maintaining HPV vaccination programs. The questionnaire consisted of 26 close-ended 
questions regarding current national cervical cancer screening and vaccination practices. 
Further, it covered current screening methods, the target group for screening, screening 
intervals, coverage of screening as per national guideline as well as whether the country had 
introduced HPV vaccination, the target group for HPV vaccination, type of vaccine and 
national data on coverage of 3-dose HPV vaccination within the target group. Additionally, 
the respondents were asked to rate the perceived importance of cervical cancer screening 
and HPV vaccination within their state or territory of origin on a scale from one to eight.
To obtain information about how Pacific Island countries and territories, perceive barriers to 
the introduction or maintenance of a national HPV vaccination program, the respondents 
were asked to rank with a score of one to ten the following ten barriers to the introduction or 
strengthening of HPV vaccination: (1) Visible government endorsement of HPV vaccine 
programs, (2) Training of health workers, teachers and others involved in the HPV program, 
(3) Well coordinated planning and implementation, (4) Good communication and 
engagement of communities, (5) Appropriate education messages, (6) Having sustainable 
financing for a long term HPV vaccine program, (7) Availability of a national monitoring 
mechanism to support HPV vaccine programs, (8) Clear guidelines/policy for HPV 
vaccination, (9) Public perception of value/safety of the HPV vaccine and (10) Other 
barriers. The barriers listed where deducted from previous recommendations from successful 
cervical cancer prevention programs (Garland et al., 2008a; Garland et al., 2008b; Garland et 
al., 2012). Barriers were subsequently grouped as highly important (score of ten to eight), of 
medium importance (score of seven to four) or of low importance (score of three to one) and 
for each barrier the proportions of countries that reported each barrier of high, medium or 
low importance were calculated.
As the questionnaire aimed to assess not only the current vaccination and screening 
practices, but also the perceived importance, barriers and intent of vaccination 
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implementation, the target groups were the “heads of health” in the region, represented by 
the administrative chief of health below the minister of health. Government. titles vary 
between the countries and territories in the region; hence the specific title of the heads of 
health would vary, but typically being: “Director of Health” or “Secretary of Health”. The 
questionnaire was sent to 21 heads of health. Pitcairn Island was not included due to small 
population size (n<60). To assist the heads of health in providing the technical details for the 
questionnaire, the questionnaire was also distributed to national focal points for the Pacific 
Society for Reproductive Health, a charitable trust for strengthening the professional 
development of sexual, reproductive and neonatal health care professionals in the Pacific. In 
the United States Affiliated Pacific Islands (American Samoa, Guam, Northern Mariana 
Islands, Federated States of Micronesia (FSM), Marshall Islands and Palau) information was 
retrieved by distributing the questionnaire to the cancer program officers in each 
jurisdictions and the University of Hawaii who together with the Center for Disease Control 
and Prevention, Division of Cancer Prevention and Control had surveyed cervical cancer 
prevention activities in the US Affiliated Pacific Islands in 2011 and again in 2013 
(Townsend et al., 2014).
The first questionnaires were sent mid October 2013 and the last end December 2013. If 
countries or territories did not respond, or clarifications were needed, communication via e-
mail and in some cases telephone was initiated within two weeks of distributing the 
questionnaires. Two countries, Solomon Islands and Vanuatu, were visited by one of SPC 
field workers in order to obtain answers to the questionnaires. All data was entered into an 
Excel data sheet and analysis was performed in Excel.
Results
All 21 countries and territories replied to the questionnaires: however 3 countries (Tuvalu, 
Wallis and Futuna and Marshall Islands) did not respond to the questions regarding the 
perceived importance of screening and vaccination, whilst 5 countries did not rate the 
barriers to HPV vaccination (Tuvalu, Wallis and Futuna, Marshall Islands, Northern 
Mariana Islands and Niue).
Cervical cancer screening practices in the pacific region
Figure 1 maps the current national screening practices within the Pacific Region. Eleven 
countries and territories (American Samoa, Cook Islands, Palau, Tokelau, French Polynesia, 
New Caledonia, Guam, Northern Mariana Islands, FSM, Fiji and Marshall islands) out of 
the 21 currently implement screening programs based on cytological screening or a 
combination of cytology and HPV test or cytology and visual inspection. Ten countries and 
territories (Kiribati, Nauru, Niue, Samoa, Solomon Islands, Tonga, Vanuatu, Papua New 
Guinea, Tuvalu and Wallis and Futuna) do not have a screening program or only screen 
opportunistically for cervical cancer. In the case of Papua New Guinea, a formal screening 
policy exists; however the coverage of the screening program is reported to only reach 1% 
of eligible women.
All countries and territories that implement cervical cancer screening were asked to report 
on the coverage of their screening programs, i.e. the proportion of eligible women screened 
Obel et al. Page 4













according to the national guideline. Tokelau reported 100% coverage. New Caledonia 
reported not having a fully functioning monitoring mechanism but estimated coverage at 
50–60%. Fiji reported to have no monitoring mechanism in place, but 8% coverage has been 
reported elsewhere (Law et al., 2013). The remaining 7 countries reported screening 
coverage rates of 4–39% among eligible women.
HPV vaccination practice in the pacific region
Figure 2 maps the current HPV vaccination practices within the Pacific Region. 10 countries 
and territories (New Caledonia, Cook Islands, FSM, Fiji, Guam, Kiribati, Wallis and Futuna, 
Marshall Islands, Northern Mariana Islands and Palau) reported HPV vaccination to be 
included in their national immunization schedule. Three countries (American Samoa, Nauru 
and Vanuatu) had not yet started to implement national vaccination but Ministry of Health 
officials reported that a national HPV vaccination program was planned for implementation 
within the next year or two. Six countries (Niue, Samoa, Solomon Islands, Tokelau, Tonga 
and Tuvalu) had not introduced the vaccine and two countries and territories (Papua New 
Guinea and French Polynesia) had implemented the vaccine in pilot sites only or provided 
the vaccine opportunistically through the private sector.
In the 10 countries and territories that had included HPV vaccination in their national 
immunization schedule, only five states and territories reported national coverage rates of 
fully immunized girls. Three countries and territories (New Caledonia, Wallis and Futuna 
and Palau) reported not having a monitoring system in place to measure vaccine coverage. 
Cook Island reported high coverage (93%) of HPV dose two, but that the third dose of HPV 
vaccine had not been provided as the vaccine was out of stock. Fiji had just very recently 
introduced the vaccine and reported high coverage of 92% out of the vaccine eligible 
population for the first dose of HPV vaccine, but no available data regarding second and 
third dose coverage. Four countries and territories (Guam, Kiribati, Marshall Island and 
Northern Mariana Island) reported coverage rates ranging 2–56%. The Federated States of 
Micronesia reported coverage rates for each island as opposed to overall coverage with 
coverage varying between <5%–89%.
The perceived importance of cervical cancer screening and HPV vaccination
Countries and territories were asked to rank the importance of HPV vaccination and cervical 
cancer screening on a scale from 1 to 8, with eight being the most important. Eighteen of 21 
countries and territories replied to this question.
Fifteen of the 18 countries and territories ranked cervical cancer screening importance as 
high (score of seven to eight). The mean score of all countries and territories was 7.3. When 
asked about the importance of HPV vaccination, all countries and territories with the 
exception of French Polynesia, Samoa, Solomon Island and Niue (14 out of 18) ranked the 
importance the highest possible (score 8). The mean score for importance of HPV 
vaccination across countries and territories was found to be 7.4.
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Barriers to introduction of vaccination
Figure 3 presents how countries and territories ranked each barrier to vaccine introduction: 
highly important (rank 8 to 10), medium important (rank 4 to 7) and less important (rank 1 
to 3). Sustainable long-term financing for HPV vaccination programs was ranked as a highly 
important barrier by the vast majority of countries and territories (88%). Only Papua New 
Guinea ranked sustainable financing as a less important barrier to HPV vaccine introduction. 
Visible government endorsement, public perception of value/safety of the HPV vaccine and 
clear guidelines/policy for HPV vaccination was respectively the 2nd, 3rd and 4th highest 
ranked barrier to introduction and maintenance of national HPV vaccination programs.
Availability of a national monitoring mechanism and appropriate education messages was 
rated as the least important barrier to national HPV vaccination programs. There was no 
clear difference in the ranking of barriers between countries and territories that are currently 
vaccinating against HPV and those that have not embarked on HPV vaccination.
Discussion
Pacific countries and territories rated the importance of both screening and HPV vaccination 
high on their public health agenda. Most countries and territories had a national policy to 
implement cervical cancer screening programs, including a screening interval, eligible target 
population and screening method but only few countries had data to report on the 
performance of the implementation of their screening program. Where coverage of cervical 
cancer screening could be reported, it generally ranged low among women eligible for 
screening according to the national screening guideline. Approximately half of the Pacific 
countries and territories had included HPV vaccination in their national immunization 
program; however most countries and territories reported coverage rates below 50%. 
Sustainable financing for long term HPV vaccination was in all but two countries rated as a 
key barrier to introduction and/or maintenance of national HPV vaccination programs, 
followed by visible government endorsement, public perception of value/safety of the HPV 
vaccine and clear guidelines/policy for HPV vaccination in that order.
The monitoring mechanisms to measure performance and coverage of national screening 
programs were weak and the majority of states and territories report coverage levels 
comparable to those reported from Sub-Saharan Africa and low income Asian countries 
such as Myanmar, Nepal and Laos (Akinyemiju, 2012). Only few other studies from the 
region have assessed coverage of cervical cancer screening, and with the exception of 
Guam, these studies confirm low coverage of cervical cancer screening in the Pacific Region 
(Mishra et al., 2001; Balajadia et al., 2008; McAdam et al., 2010; Aruhuri et al., 2012; 
Hernandez et al., 2013; Law et al., 2013). A recent study from the US Affiliated Guam, 
American Samoa, Northern Mariana Islands, Federated States of Micronesia and Marshall 
Islands) examined the practices, attitudes and knowledge of health care workers on cervical 
cancer screening (Townsend et al., 2014). Screening was considered a high priority in 
clinical practice, although the cost associated with screening as well as quality assurance to 
ensure coverage of all eligible women and that abnormal test results are followed in a timely 
manner were perceived as key barriers to reducing the cervical cancer burden (Townsend et 
al., 2014).
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Even though cervical cancer screening is an effective measure to reduce the burden of 
cervical cancer, programs are highly dependent on: health seeking behavior among women, 
access to service delivery points, training of health personnel and appropriate means of 
follow-up for screening-positive cases and a well resourced comprehensive national 
screening program. Furthermore, the choice of screening tests requires careful assessment 
and adaptation to national circumstances. The regional research based body Asia Oceania 
Research Organisation in Genital Infections and Neoplasia (AOGIN) has developed a 
guideline for cervical cancer screening in Asia-Oceania for both low- and high income 
countries which could serve as a guide for Pacific countries and territories regarding 
screening test method (Ngan et al., 2011). The findings of this study suggest that monitoring 
mechanisms to measure screening program performance and enhance coverage within 
Pacific countries and territories should be strengthened as a means to effectively prevent 
cervical cancer in this Region. A successful implementation of high level coverage of HPV 
vaccination in the Pacific Islands and thus reduction in the rates of cervical dysplasia 
reduces the sensitivity of the screening tests, and HPV DNA may in the future be 
recommended as the primary screen test (WHO, 2014a).
Ten out of 21 Pacific countries and territories currently have a policy to implement HPV 
vaccination on a national scale. This number is significantly higher than what was found by 
retrieving national immunization data year 2012 from the global WHO database on vaccine-
preventable diseases. The WHO database reports immunization schedules for 13 out of the 
21 Pacific Island countries and territories, and reported that only four countries had included 
the HPV vaccine in the national immunization schedule at that time (WHO, 2013).
The majority of the ten Pacific countries and territories that has a policy to implement 
national scale HPV vaccination reported either no monitoring mechanism for measuring 
national HPV vaccination coverage or limited coverage, below 60% among the eligible 
population. No countries or territories had to our knowledge conducted base line surveys to 
measure HPV genotype prevalence or prevalence of cervical dysplasia before commencing 
national vaccination against HPV. Only two studies from the Pacific Region have reported 
genotype prevalence in healthy women. Both studies were carried out among women in 
Vanuatu and may in the future serve as baseline for measuring vaccine effectiveness when 
the plans for HPV vaccine introduction in Vanuatu are implemented Jurisdictions (Palau, 
(McAdam et al., 2010; Aruhuri et al., 2012).
A limitation of the study was that only one representative from each Ministry of Health 
reported on the national cancer prevention situation. The grading of importance of screening 
and vaccination as well as barriers to introduction and/or maintenance of national HPV 
vaccination programs may represent the opinion and perception of only the one informant or 
a wider group of health professionals, depending on the method the informant used to gather 
information for the questionnaire. A strength of the study is the good coverage of the region, 
with 21 officials from 21 Ministries of Health responding fully or partly on the 
questionnaire.
The introduction and maintenance of a high coverage HPV vaccination program in the 
Pacific could be a highly effective approach to reducing the burden of cervical cancer, 
Obel et al. Page 7













premature deaths and potentially other HPV related cancers (vulvar, vaginal, anal cancer and 
oro-pharyngeal cancers) (Garland et al., 2007; Garland, 2011). Global estimates and two 
studies from the Pacific Region of HPV genotype prevalence in women with cervical cancer 
predict that high coverage of HPV vaccination against HPV16 and 18 among HPV naïve 
women can prevent approximately 70–80% of cervical cancer cases (Clifford et al., 2003; 
Tabrizi et al. 2011; Tabone et al., 2012). With the recently FDA approved nine-valent HPV 
vaccine, protection could be as high as 90–95% (Joura et al.,2014). Studies from countries 
where high coverage levels has been achieved have found reduced prevalence of genital 
warts and pre-cancerous cervical lesions among both the vaccinated and un-vaccinated 
populations, indicating herd immunity with a reduction in the circulating pool of HPV virus 
(Ali et al., 2013; Baandrup et al., 2013; Gertig et al., 2013; Baldur-Felskov et al., 2014).
Current HPV vaccination regimes rely on vaccinating girls aged 9 years and above, before 
sexual debut. The introduction of the HPV vaccine falls outside the current scope of the 
national EPI programs which generally targets children age 0–12 months of age. School-
based delivery mechanisms have been shown to be effective in reaching high vaccine 
coverage levels (Garland et al., 2008a). A recent multi-country study from Peru, Uganda and 
Vietnam assessed the feasibility and cost of vaccine delivery per fully immunized girl. The 
study found the school-based delivery mechanism to be more costly than health-center-
based delivery or integrated approaches which combined school and health-center based 
delivery with the average delivery cost per dose USD 3.88–2.08 for school based delivery, 
USD 1.92 for health center based delivery and USD 1.44 for integrated delivery. The 
delivery costs varied between countries. Albeit more costly, school-based delivery 
mechanisms achieved substantially higher coverage rates (82.6–88.9%) than delivery 
through integrated approaches (60.7%). No coverage estimate was provided among the 
population in which HPV vaccination was delivered via health facilities only (Levin et al., 
2013).
HPV vaccine prices have recently been reduced in GAVI countries (Solomon Island and 
Papua New Guinea) in the region. These countries can purchase vaccines at a significantly 
reduced price of 4.5 USD per dose if they are able to establish and show capacity to 
maintain a high coverage level among the target groups via pilot studies (GAVI, 2013). At 
this level of vaccine price, a regional cost-effectiveness study from the Asia-Pacific suggest 
HPV vaccination to be cost-effective, using annual gross domestic product (GDP) per capita 
as the cost-effectiveness threshold (Goldie et al., 2008). A recent systematic review of cost-
effectiveness of HPV vaccination in low- and middle-income countries confirms these 
findings and also suggests that HPV vaccination is particularly likely to be cost-effective in 
settings without an organized cervical cancer screening program (Fesenfeld et al., 2013). In 
Latin America, a regional financing mechanism via the Revolving Fund of the Pan 
American Health Organization (PAHO) has been able to lower the HPV vaccine price to 
USD 10–15 per dose through negotiation with the vaccine companies and bulk purchases 
(Levin et al., 2013). New developments with the introduction of a two-dose instead of the 
three-dose regime will further increase cost-effectiveness as well as simplify delivery and 
lead to improved coverage rates (Dobson et al., 2013; WHO, 2014b). Packaging HPV 
vaccination programs with national adolescent health efforts targeting sexual risk behavior, 
Obel et al. Page 8













substance abuse, under- and over nutrition and physical inactivity could additionally 
increase cost-effectiveness of the intervention (Broutet et al., 2013).
The Pacific Region is inhabited by approximately 10.5 million people distributed over 22 
islands countries and territories with population sizes ranging from below 1,000 to 
approximately 7 million people (Secretariat of the Pacific Community, 2013). Individual 
small countries have limited bargaining power to reduce the vaccine related costs. Across 
the Pacific Island countries and territories, sustainable financing mechanisms for the 
introduction and/or maintenance of HPV vaccination programs was highlighted as a key 
barrier to HPV vaccination. Building upon the experience from the PAHO Revolving Fund, 
a regional financing mechanism in collaboration with neighboring highly populated 
countries in Asia-Oceania may be a promising avenue to explore as a means to reduce 
vaccine prices and thereby increasing the cost-effectiveness of the intervention (Andrus et 
al., 2008).
The cervical cancer disease burden in the Pacific Region is high, especially in the 
Melanesian countries where incidence ranks among the world’s highest (Ferlay et al., 2010; 
Garland et al., 2012; Obel et al., 2014). Current preventive efforts in the region do not match 
the burden of disease. In countries where HPV vaccination and screening has been 
introduced, the coverage levels are generally low. The Pacific Region consists of many 
small countries and territories, and several international development partners are engaged 
in the field of reproductive health and cervical cancer prevention. This situation calls for a 
regional concerted effort to coordinate and support the introduction of the HPV vaccine. A 
regional approach, ensuring momentum and technical support for strengthening operational 
research and national monitoring mechanisms as well as building capacity among health 
workers and other stakeholders could reduce the burden on national health systems, enhance 
the quality of prevention programs and ensure continuous learning from successful national 
programs. As has been the case previously in other regions with the cancer-preventing 
hepatitis B virus vaccine (Colombara and Wang, 2013), a very powerful intervention may be 
delayed for several years if we fail to coordinate stakeholders and achieve political 
momentum for cervical cancer prevention, risking the lives of many women in the Pacific 
Region.
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Barriers to Introduction and Implementation of National HPV Vaccination Programs in the 
Pacific Region, 2013.*Barriers under the category “Other barriers” were: Lack of quality 
standards for vaccines and cold chains; Lack of human resources; Lack of national 
champions to drive the process of vaccine introduction; Lack of acceptance for school-based 
vaccination among school authorities and school nurses; Lack of awareness campaigns 
targeting parents
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